FDA Inspections: Before, During and After - In-person Comprehensive Workshop

May
 7 - 8 
v
FOUR POINTS BY SHERATON FRENCH QUARTER, New Orleans, LA, USA
View Map

Overview:

FDA's inspection program follows well-established procedures and conducts the inspections with as much consistency as possible. FDA trains its investigators from day one. During the first six months, they attend extensive classroom and hands on training. FDA investigators learn basic skills. As time goes on, special training is given and the field staff use detailed reference materials to guide their thinking, actions, decisions and conclusions. If you understand FDA's management of its investigators and inspectional process, you can keep your establishment ahead of a needless regulatory disaster. FDA conducts inspections with standard operating procedures and detailed information on how to handle almost any situation the FDA investigator may face. The course will let you see inside an FDA investigator's mind set and what the agency will do when it evaluates what the investigator says and documents. What the investigator does and what FDA does are not mysteries, they just seem like it.


Why should you attend:

"Hi, I'm from the FDA and here to conduct an inspection." What is the first thing you do? Ring a fire alarm, close down for the day (some firms have) or do you follow well-planned protocol. You think, "Why is FDA here? Are we in trouble?" Are you prepared to talk about the trouble you know you have with FDA regulations or is your plan of action to cross your fingers.

We all know that a bad FDA inspection has immediate and long-term consequences. The cost of fixing your problems, the bad public relations, upset customers and future business plans can be set into a downward spiral. If you do not understand what FDA is doing or thinking, how can you expect to deal successfully with FDA? If you don't know how to anticipate an investigator's actions or follow their train of thought, you will not be able to mitigate the effect of inspectional findings.

"Is FDA going to send us a Warning Letter?" You can make a reasonable prediction if you understand your inspectional results and how FDA will "grade" it. The tools are available.


Areas Covered in the Session:

  • FDA legal authority
  • Types of inspections
  • FDA investigator training
  • FDA's written procedures, policy and operations guide
  • Industry inspection protocol
  • What to do and not do during an inspection
  • Form FDA 483 response
  • Warning Letter response
  • Enforcement

Who will benefit:

  • Regulatory Affairs
  • Quality Assurance
  • Manufacturing

Agenda

Day One

Lecture 1: FDA Inspection authority

  • FDA Inspection authority
  • Inspectional refusal prohibition

Lecture 2: Types of Inspections: purpose, scope and scrutiny

  • Comprehensive GMP
  • Abbreviated GMP
  • District or Center Directed
  • Regulatory Follow-up
  • Surveillance
  • Limited
  • For Cause

Lecture 3: Impact on you during and after inspection

  • How to interact with the FDA investigator
  • What not to say and do
  • Your protocol
  • Mismanagement of the inspection

Lecture 4: FDA Investigator Training - This is what they are thinking

  • On the job training and supervision
  • Technical, classroom and mock inspections
  • Evidence development to tell the story
  • Physical and documentary samples of your violations
  • Writing reports, inspectional observations and sample documentation
  • Physical threats and assault

Lecture 5: Investigations Operations Manual

  • Procedures and technical guidance. FDA's rules for themselves
  • FDA organization chart "in the field." Who is watching you?

Compliance Programs

  • Section III - the inspection / specific issues
  • Section V - the regulatory response / risk assessment

Lecture 6: Investigations Operations Manual (continued)

Mock "Limited" inspection

  • Writing inspectional observations (Form FDA 483)
  • Writing establishment inspection reports
  • Evidence documentation and custody

Day Two

Lecture 1: FDA Form 483 - List of objectionable conditions, aka list of observations

  • Purpose
  • Format / organization
  • Managing 483 observations during the inspection
  • Responding to 483 observations during "discussion with management"
    • What it means
    • How to manage the discussion
    • How to challenge a 483 observation
    • What to say and not say

Lecture 2: Your written response to a 483

  • Understanding the 483 - using an FDA issued 483
  • Time deadlines
  • Strategy for corrections and corrective action
  • Evidence of corrections and corrective action
  • Empty promises

Lecture 3: FDA Warning Letter - advisory of possible legal action

  • FDA Warning Letter procedures
  • Responding to a Warning Letter - in 15 working days.

Group Hypothetical Warning Letter Response - in 10 minutes


Lecture 4: FDA Enforcement Actions

  • Judicial
    • Seizure
    • Injunction
    • Prosecution
    • Monetary penalties
  • Administrative
    • Import / Export
    • Government contracts
    • Other government agency advisories
    • Fines
    • Premarket holds

Speaker:

Casper (Cap) Uldriks

ex-FDA Expert and former Associate Center Director of CDRH, Olsson 

Casper (Cap) Uldriks through his firm "Encore Insight LLC," brings over 32 years of experience from the FDA. As an investigator, he was responsible for countless 483s, scores of Warning Letters, injunctions, individual seizures, mass seizures and was coined by industry as FDA's "Darth Vader." 

Price: $1,295.00 

Quick Contact:

NetZealous BDA as GlobalCompliancePanel 
        
USA Phone:1-800-447-9407
Fax: 302-288-6884
support@globalcompliancepanel.com    
http://www.globalcompliancepanel.com

Speakers


ex-FDA Expert and former Associate Center Director of CDRH, Olsson
Encore Insight LLC

Join the conversation

Upcoming events

Complaint-Handling, MDR and Recall Management - 2-day In-person Seminar

l19 Mar 15 | 9:00

Overview: An effective complaint handling system is an extremely important...

Q

2-day In-person Seminar - The A to Z's of Microbial Control, Monitoring

l9 Apr 15 | 9:00

Overview: This course is designed to provide a microbiology-focused education...

Q

2-day In-person Workshop on Enforcing Effective SOPs (Standard Operating Procedures)

l9 Apr 15 | 9:00

Overview: Writing SOPs or procedural documents can be challenging at times....

Q

Managing Advanced Research & Development - 2-day Comprehensive Workshop

l9 Apr 15 | 9:00

Overview: This webinar will cover issues concerning industrial / scientific...

Q

Accreditation to ISO/IEC 17025:2005- Getting There is Only Half the Fun! - 2-day In-person Seminar

l23 Apr 15 | 9:00

Overview: QMS is the catch phrase for accreditation and is the backbone of...

Q

Seminar on The A to Z's of Writing and Enforcing Effective SOPs (Standard Operating Procedures)

l14 May 15 | 9:00

Overview: Writing SOPs or procedural documents can be challenging at times....

Q

Preparing to Comply with the New FDA FSMA Rules on the Sanitary Transportation of Human

l14 May 15 | 9:00

Overview: Transportation and Logistics food transportation food safety rules...

Q

GMP and Regulatory Expectations for Early IND Products

l21 May 15 | 9:00

Overview: This course will present, in one place, the regulations and...

Q

Human Subjects Research Seminar: Current Regulations under FDA and HIPAA at San Diego, CA

l4 Jun 15 | 9:00

Overview: This two day seminar will provide the foundation for the...

Q

2-day In-person Seminar on Extracting Information from Geochemical Data at Salt Lake City, UT

l4 Jun 15 | 9:00

Overview: Most specialists strongly recommend to sample every meter of the...

Q

Seminar on Quality Assurance for Microbiological Laboratories at Chicago

l4 Jun 15 | 9:00

Overview: QMS is the catch phrase for accreditation and is the backbone of...

Q

2-day In-person Seminar on Using Statistical Methods for ICH Guidelines at Barcelona, Spain

l8 Jun 15 | 9:00

Overview: This hands-on course will provide attendees with an understanding of...

Q

2-day In-person Seminar on Submitting Marketing Applications in Canada at Seattle, Washington

l18 Jun 15 | 9:00

Overview: Topics included will include the filing of New Drug Submissions for...

Q